Navigation Links
New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014
Date:8/19/2010

WALTHAM, Mass., Aug. 19 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, new coverage instituted under the Patient Protection and Affordable Care Act of 2010 will remove the financial disincentives associated with colorectal cancer screening for a large segment of the US population. As a result of these changes in reimbursement, a growing number of colorectal cancer screening procedures will be performed through 2014, driving sales of many gastrointestinal endoscopy devices, including videoscopes and biopsy forceps.

Under the health care act, all new health insurance policies must cover preventative exams, including colonoscopies, without charging out-of-pocket fees such as copayments or deductibles. All Medicare patients will therefore have colorectal cancer screening colonoscopies fully covered as of January 1, 2011. This expanded coverage of colorectal cancer screening procedures will increase the number of colonoscopies performed over the next five years. Sales of devices used in the procedures, such as colonoscopes and biopsy forceps, will also rise to meet this growing demand for colorectal cancer screening. Although colonoscopy volumes dipped in 2009 during the recession, they are climbing again and will continue to rise as increased medical insurance coverage encourages more Americans to undergo screening.

"At the height of the economic downturn, many Americans declined to undergo colorectal cancer screening because they lost insurance coverage for it or they felt that paying for a diagnostic procedure when they did not have any symptoms was not a priority for them in economically uncertain times," said Sara Scharf, Ph D, Analyst at MRG. "As this new coverage is put in place, patients will increasingly get screened for colorectal cancer."

MRG's new report, US Markets for Gastrointestinal Endoscopy Devices 2010, now includes more segments, detailed competitor coverage, and insights into trends than ever before. The report provides a thorough analysis of procedural trending, emerging markets, competing and complementary procedures, and revenue growth for the major gastrointestinal endoscopy devices in the US, including videoscopes, enteral feeding devices, endoscopic retrograde cholangiopancreatography devices, hemostasis devices, biopsy forceps, stents, virtual colonoscopy systems, esophageal dilation balloons, capsule endoscopes, polypectomy snares, and retrieval devices. For the first time, this report includes market analyses of enteral feeding giving sets, nasogastric tubes, colonic and duodenal stents, and Barrett's esophagus ablation devices.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-296-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
2. For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
5. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
6. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
7. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
8. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
9. ARUP Laboratories Applauds FDAs Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
10. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
11. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Dickinson Insurance and Financial Services, a ... services, is providing an update on a charitable event that began earlier this ... a locally recognized nonprofit that provides shelter and care for animals seeking new ...
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
Breaking Medicine News(10 mins):